Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutrition 21 faces payment milestone

This article was originally published in The Tan Sheet

Executive Summary

The nutritional bioscience firm's revenues grow $500,000 to $2.7 million in its fiscal 2010 fourth quarter, trimming its net loss to $43,000 from $700,000 in the year-ago quarter. Purchase, N.Y.-based Nutrition 21 also cut its net loss for the full year, to $1.8 million from $4.2 million, as full-year revenues grew from $7.7 million to $8.8 million. In a Sept. 23 release, CEO Michael Zeher said the firm must pay approximately $17.8 million to satisfy a requirement to redeem preferred stock in September 2011. Nutrition 21 also will need to issue significant additional common shares if the firm's share price "remains at very low levels" and if it continues to pay preferred dividends in stock, Zeher added. The firm said its fiscal improvement for the year comes from selling its Branded Products Group during its second quarter, an emphasis on expense controls, sales led by chromium picolinate and the launch of new products

You may also be interested in...

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts